Biogened (BGD) Stock Overview
Produces and sells cosmetics and toiletries in Poland. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
BGD Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Biogened S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł22.80 |
| 52 Week High | zł32.00 |
| 52 Week Low | zł17.30 |
| Beta | 0.20 |
| 1 Month Change | 27.37% |
| 3 Month Change | 6.54% |
| 1 Year Change | -14.93% |
| 3 Year Change | 68.89% |
| 5 Year Change | 94.87% |
| Change since IPO | -43.00% |
Recent News & Updates
Recent updates
Biogened (WSE:BGD) Will Pay A Dividend Of PLN0.50
Sep 09
Biogened's (WSE:BGD) Promising Earnings May Rest On Soft Foundations
Aug 23Market Participants Recognise Biogened S.A.'s (WSE:BGD) Earnings
Aug 15Biogened (WSE:BGD) Has A Pretty Healthy Balance Sheet
Jul 11Investors Interested In Biogened S.A.'s (WSE:BGD) Earnings
May 01Investors Appear Satisfied With Biogened S.A.'s (WSE:BGD) Prospects As Shares Rocket 44%
Jan 20Investors Give Biogened S.A. (WSE:BGD) Shares A 27% Hiding
Dec 06Biogened (WSE:BGD) Takes On Some Risk With Its Use Of Debt
Nov 06A Piece Of The Puzzle Missing From Biogened S.A.'s (WSE:BGD) 25% Share Price Climb
Aug 28Impressive Earnings May Not Tell The Whole Story For Biogened (WSE:BGD)
Aug 22Investors Give Biogened S.A. (WSE:BGD) Shares A 37% Hiding
May 23Here's Why Biogened (WSE:BGD) Has A Meaningful Debt Burden
May 09Biogened's (WSE:BGD) Promising Earnings May Rest On Soft Foundations
Feb 21Is Biogened (WSE:BGD) A Risky Investment?
Feb 01Biogened S.A. (WSE:BGD) Looks Just Right With A 37% Price Jump
Feb 01We Think Biogened (WSE:BGD) Can Stay On Top Of Its Debt
Jun 30Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly
Oct 08Is Biogened (WSE:BGD) A Risky Investment?
Jun 29Does Biogened (WSE:BGD) Have A Healthy Balance Sheet?
Mar 25These 4 Measures Indicate That Biogened (WSE:BGD) Is Using Debt Reasonably Well
Dec 09Biogened (WSE:BGD) Has A Somewhat Strained Balance Sheet
Jul 29Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly
Apr 30Is Biogened (WSE:BGD) A Risky Investment?
Jan 24Shareholder Returns
| BGD | PL Pharmaceuticals | PL Market | |
|---|---|---|---|
| 7D | 31.0% | -0.7% | 2.3% |
| 1Y | -14.9% | -15.7% | 32.2% |
Return vs Industry: BGD matched the Polish Pharmaceuticals industry which returned -15.7% over the past year.
Return vs Market: BGD underperformed the Polish Market which returned 32.2% over the past year.
Price Volatility
| BGD volatility | |
|---|---|
| BGD Average Weekly Movement | 14.1% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in PL Market | 10.9% |
| 10% least volatile stocks in PL Market | 3.1% |
Stable Share Price: BGD's share price has been volatile over the past 3 months compared to the Polish market.
Volatility Over Time: BGD's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Polish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 195 | Andrzej Grzegorzewski | www.biogened.pl |
Biogened S.A. produces and sells cosmetics and toiletries in Poland. The company offers dermo-cosmetics under the Dermedic brand; and thermal water. It also exports its products.
Biogened S.A. Fundamentals Summary
| BGD fundamental statistics | |
|---|---|
| Market cap | zł60.92m |
| Earnings (TTM) | zł4.62m |
| Revenue (TTM) | zł114.04m |
Is BGD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BGD income statement (TTM) | |
|---|---|
| Revenue | zł114.04m |
| Cost of Revenue | zł41.00m |
| Gross Profit | zł73.04m |
| Other Expenses | zł68.42m |
| Earnings | zł4.62m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 15, 2026
| Earnings per share (EPS) | 1.88 |
| Gross Margin | 64.05% |
| Net Profit Margin | 4.05% |
| Debt/Equity Ratio | 47.0% |
How did BGD perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/17 17:07 |
| End of Day Share Price | 2026/04/17 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Biogened S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.